Tecentriq + chemotherapy improved overall survival in IMpower133 study for first line SCLC.- Roche

Roche announced positive results from the Phase III IMpower133 study of Tecentriq (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC).

The analysis showed that Tecentriq and chemotherapy helped people live significantly longer compared with chemotherapy alone (overall survival [OS]=12.3 versus 10.3 months; hazard ratio [HR]=0.70, 95% CI: 0.54-0.91; p=0.0069) in the intention-to-treat (ITT) population. The Tecentriq -based combination also significantly reduced the risk of disease worsening or death (progression-free survival, PFS) compared with chemotherapy alone (PFS=5.2 versus 4.3 months; HR=0.77, 95% CI: 0.62-0.96; p=0.017). Safety for the Tecentriq and chemotherapy combination appeared consistent with the combination.

See- "First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer"-Leora Horn, M.D., Aaron S. Mansfield, M.D., Aleksandra Szcz?sna, M.D., , et al., for the IMpower133 Study Group-September 25, 2018. DOI: 10.1056/NEJMoa1809064.